OBJECTIVE: To determine the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaoundé, Cameroon. DESIGN: The study was a prospective Public Health Pilot Program covering a 3-year period (January 2000-December 2002). METHODS: Counseled and consenting HIV-1-positive pregnant women were given a single dose of NVP at the onset of labor. Babies were given 2 mg/kg NVP syrup within the first 72 hours of life. NVP-treated children were regularly followed up and examined for HIV-1 infection at 6-8 weeks and 5-6 months through plasma viral load (VL) quantification with the bDNA system. RESULTS: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 weeks and 5-6 months. Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL. Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points. One hundred seven children (87%) were considered not infected at 6-8 weeks of age. CONCLUSIONS: Our results indicate that the HIV-1 MTCT rate 6-8 weeks after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.
OBJECTIVE: To determine the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaoundé, Cameroon. DESIGN: The study was a prospective Public Health Pilot Program covering a 3-year period (January 2000-December 2002). METHODS: Counseled and consenting HIV-1-positive pregnant women were given a single dose of NVP at the onset of labor. Babies were given 2 mg/kg NVP syrup within the first 72 hours of life. NVP-treated children were regularly followed up and examined for HIV-1 infection at 6-8 weeks and 5-6 months through plasma viral load (VL) quantification with the bDNA system. RESULTS: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 weeks and 5-6 months. Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL. Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points. One hundred seven children (87%) were considered not infected at 6-8 weeks of age. CONCLUSIONS: Our results indicate that the HIV-1 MTCT rate 6-8 weeks after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.
Authors: Christopher F Rowley; Christian L Boutwell; Esther J Lee; Iain J MacLeod; Heather J Ribaudo; M Essex; Shahin Lockman Journal: AIDS Res Hum Retroviruses Date: 2010-03 Impact factor: 2.205
Authors: Cristina M Marazzi; Paola Germano; Giuseppe Liotta; Giovanni Guidotti; Sandra Loureiro; Aurelio da Cruz Gomes; Maria C Valls Blazquez; Pasquale Narciso; Carlo F Perno; Sandro Mancinelli; Annamaria Doro Altan; Karin Nielsen-Saines; Leonardo Palombi Journal: Eur J Pediatr Date: 2007-01-18 Impact factor: 3.183
Authors: Elizabeth M Stringer; Benjamin H Chi; Namwinga Chintu; Tracy L Creek; Didier K Ekouevi; David Coetzee; Pius Tih; Andrew Boulle; Francois Dabis; Nathan Shaffer; Catherine M Wilfert; Jeffrey S A Stringer Journal: Bull World Health Organ Date: 2008-01 Impact factor: 9.408
Authors: A E Ezeamama; C Duggan; K P Manji; D Spiegelman; E Hertzmark; R J Bosch; R Kupka; J O Okuma; R Kisenge; S Aboud; W W Fawzi Journal: HIV Med Date: 2013-11-11 Impact factor: 3.180
Authors: Benjamin H Chi; Moses Sinkala; Elizabeth M Stringer; Ronald A Cantrell; Velepi Mtonga; Marc Bulterys; Isaac Zulu; Chipepo Kankasa; Catherine Wilfert; Paul J Weidle; Sten H Vermund; Jeffrey S A Stringer Journal: AIDS Date: 2007-05-11 Impact factor: 4.177
Authors: Zandrea Ambrose; Sarah Palmer; Valerie F Boltz; Mary Kearney; Kay Larsen; Patricia Polacino; Leon Flanary; Kelli Oswald; Michael Piatak; Jeremy Smedley; Wei Shao; Norbert Bischofberger; Frank Maldarelli; Jason T Kimata; John W Mellors; Shiu-Lok Hu; John M Coffin; Jeffrey D Lifson; Vineet N KewalRamani Journal: J Virol Date: 2007-09-12 Impact factor: 5.103
Authors: Wei Shao; Mary Kearney; Frank Maldarelli; John W Mellors; Robert M Stephens; Jeffrey D Lifson; Vineet N KewalRamani; Zandrea Ambrose; John M Coffin; Sarah E Palmer Journal: Retrovirology Date: 2009-11-04 Impact factor: 4.602